Regression of Corneal Neovascularization Secondary to Allergic Keratoconjunctivitis through Intrastromal Treatment with HeberFERON®
Keywords:
allergic keratoconjunctivitis; corneal neovascularization; HeberFERON®; shield ulcer.Abstract
Introduction: Allergic keratoconjunctivitis is the most common condition in the pediatric and adolescent population. In its most severe forms, it can cause corneal alterations.
Objective: To present a new therapeutic option that combines the antiangiogenic effect of alpha and gamma interferons in the regression of corneal neovessels.
Case presentation: We present an 18-year-old female patient diagnosed with chronic allergic keratoconjunctivitis, which progressed to a shield ulcer with leukoma and superficial corneal vascularization in the left eye. Despite conventional medical treatment with topical corticosteroids, antihistamines, and artificial tears, neovascularization persisted, with deterioration of visual acuity. Faced with this therapeutic resistance, an intrastromal injection of HeberFERON®, a combination of alpha and gamma interferons with antiangiogenic properties, was chosen. Three months after the procedure, a significant decrease in corneal vascularization and reduction in leukoma density was observed, with no relevant side effects.
Conclusions: HeberFERON® may represent an effective and safe alternative in complex cases of refractory corneal neovascularization, thanks to its synergistic antiangiogenic and immunomodulatory action.
Downloads
References
1. Calvo D. Conjuntivitis alérgica: revisión bibliográfica. Rev. Electrón. Portales Medicos.com. 2024 [acceso 05/01/2025];19(16). Disponible en: https://www.revista-portalesmedicos.com/revista-medica/conjuntivitis-alergica-revision-bibliografica/
2. Tariq F. Allergic Conjunctivitis: Review of Current Types, Treatments, and Trends. Life (Basel). 2024;14(6):650. DOI: https://doi.org/10.3390/life14060650
3. Özkaya D, Usta G, Karaca U. A Case of Shield Ulcer Due to Vernal Keratoconjunctivitis. Irán J Alergia Asma Immunol. 2021;20(4):505-8. DOI: https://doi.org/10.18502/ijaai.v20i4.6961
4. Wang E, Kong X, Wolle M. Global Trends in Blindness and Vision Impairment Resulting from Corneal Opacity 1984-2020: A Meta-analysis. Ophthalmology. 2023;130(8):863-71. DOI: https://doi.org/10.1016/j.ophtha.2023.03.012
5. Nicholas M, Mysore N. Corneal neovascularization. Exp Eye Res. 2021;202:108363. DOI: https://doi.org/10.1016/j.exer.2020.108363
6. Drzyzga Ł, Śpiewak D, Dorecka M, Wyględowska-Promieńska D. Available Therapeutic Options for Corneal Neovascularization: A Review. Int J Mol Sci. 2024;25(10):5479. DOI: https://doi.org/10.3390/ijms25105479
7. Fernández Y, Parra Z, Rodríguez Y, Ramírez M, Concepción ç Y. Terapias actuales en la vascularización corneal. Rev Cuba Oftalmol. 2021 [acceso 05/01/2025];34(1). Disponible en: https://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/927
8. Geindreau M, Bruchard M, Vegran F. Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context. Cancers. 2022;14(10):2446. DOI: https://doi.org/10.3390/cancers14102446
9. Kommineni V, Nagineni C, William A, Detrick B, Hooks J. IFN-γ Acts as Anti-Angiogenic Cytokine in The Human Cornea by Regulating the Expression of VEGF-A and sVEGF-R1. Biochem Biophys Res Commun. 2008;374(3):479-84. DOI: https://doi.org/10.1016/j.bbrc.2008.07.042
10. Yang Y, Zhong J, Cui D, Jensen L. Up-to-Date Molecular Medicine Strategies for Management of Ocular Surface Neovascularization. Adv Drug Deliv Rev. 2023;201:115084. DOI: https://doi.org/10.1016/j.addr.2023.115084
11. Bello J, García Y, Santana H, Duncan Y, Collazo S, Anasagasti L, et al. Desarrollo de la formulación farmacéutica que combina a los interferones alfa-2b y gamma para el tratamiento del cáncer de piel no melanoma. An Acad Cienc Cuba. 2024 [acceso 05/01/2025];14(1):e1533. Disponible en: https://revistaccuba.sld.cu/index.php/revacc/article/view/1533
12. Fernández Y, Parra Z, Rodríguez Y, Borges M, Mesa A. Aplicación de HeberFERON® en colirio como tratamiento adyuvante en la operación de pterigión. Rev Cuba Oftalmol. 2024 [acceso 05/01/2025];37. Disponible en: https://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/1869
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista Cubana de Oftalmología
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
El contenido de la revista se encuentra accesible sin costo alguno. Está protegido por los términos de la Licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional
